iX Biopharma Statistics

Total Valuation

iX Biopharma has a market cap or net worth of SGD 20.32 million. The enterprise value is 23.67 million.

Market Cap	20.32M
Enterprise Value	23.67M

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.33%
Shares Change (QoQ)	+0.25%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	480.70M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.19
EV / Sales	3.97
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.47

Financial Position

The company has a current ratio of 0.89, with a Debt / Equity ratio of 1.20.

Current Ratio	0.89
Quick Ratio	0.65
Debt / Equity	1.20
Debt / EBITDA	n/a
Debt / FCF	-0.76
Interest Coverage	-16.96

Financial Efficiency

Return on equity (ROE) is -106.91% and return on invested capital (ROIC) is -31.51%.

Return on Equity (ROE)	-106.91%
Return on Assets (ROA)	-23.69%
Return on Capital (ROIC)	-31.51%
Revenue Per Employee	141,881
Profits Per Employee	-257,000
Employee Count	42
Asset Turnover	0.30
Inventory Turnover	4.20

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -43.18% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-43.18%
50-Day Moving Average	0.03
200-Day Moving Average	0.03
Relative Strength Index (RSI)	37.52
Average Volume (20 Days)	222,410

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, iX Biopharma had revenue of SGD 5.96 million and -10.79 million in losses. Loss per share was -0.01.

Revenue	5.96M
Gross Profit	1.05M
Operating Income	-7.50M
Pretax Income	-9.99M
Net Income	-10.79M
EBITDA	-7.08M
EBIT	-7.50M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 1.84 million in cash and 5.20 million in debt, giving a net cash position of -3.36 million.

Cash & Cash Equivalents	1.84M
Total Debt	5.20M
Net Cash	-3.36M
Net Cash Per Share	n/a
Equity (Book Value)	4.34M
Book Value Per Share	0.01
Working Capital	-795,000

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -6.55 million and capital expenditures -274,000, giving a free cash flow of -6.83 million.

Operating Cash Flow	-6.55M
Capital Expenditures	-274,000
Free Cash Flow	-6.83M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 17.59%, with operating and profit margins of -125.78% and -181.14%.

Gross Margin	17.59%
Operating Margin	-125.78%
Pretax Margin	-167.56%
Profit Margin	-181.14%
EBITDA Margin	-118.88%
EBIT Margin	-125.78%
FCF Margin	-114.57%

Dividends & Yields

iX Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.33%
Shareholder Yield	-0.33%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

iX Biopharma has an Altman Z-Score of -8.52. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.52
Piotroski F-Score	n/a